Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

"I'm focused on adding value. So, in five years, this company is worth a lot more than it is today," Ricks said. Eli Lilly has been on investors' watch list as its GLP-1 business boomed to ...

The company maintained its fiscal ... Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $3.34 per share for the first ...

Eli Lilly and Company CEO David Ricks stands as President ... Lilly shares shed more than $90 in value, falling nearly 11% to $804.06 Thursday afternoon. Broader indexes, meanwhile, rose slightly.

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound ... treatments has boosted its market value to more than $800 billion, making it ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...